Skip to main content
. 2018 Dec 6;2018:3824357. doi: 10.1155/2018/3824357

Figure 1.

Figure 1

SKSF decreased FBG and HbA1c levels. (a) Fasting blood glucose, (b) HbA1c. Data were expressed as mean ± SD, n=10 rats per group. N, normal group; M, model group; Met, metformin group; SKSF-l, Spleen-Kidney Supplementing Formula group at a low dose; SKSF-m, Spleen-Kidney Supplementing Formula group at a medium dose; SKSF-h, Spleen-Kidney Supplementing Formula group at a high dose. P <0.05 compared with model group.